Financial statements are reported in AUD. Prices converted from USD at today's exchange rate. Tranches and alerts stay in USD.
KZIA — Kazia Therapeutics Limited
A$ 9.77
A$ -0.49 (-4.75%)
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors.
Market Cap
A$ 111.67M
Forward P/E
-848.7x
52-Week Range
N/A
KZIA Price History
Revenue vs. Net Income
A$ 1.9M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-A$ 13.3M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-117.7%
ROCE · FY2023
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
0.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
1.1M
Diluted shares · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
